Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 16/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160843 | 0.82 | CCR1 (0.57) | CCR1KCNH2ADAMTS5TACR3DPP4 | |
| SCHEMBL10292712 | 0.79 | CCR1 (0.51) | CCR1KCNH2ADAMTS5TACR3 | |
| SCHEMBL2159207 | 0.78 | CCR1 (0.69) | CCR1KCNH2 | |
| SCHEMBL10291820 | 0.78 | CCR1 (0.66) | CCR1KCNH2 | |
| SCHEMBL6520372 | 0.77 | EPHX2 (0.44) | CCR1 | |
| SCHEMBL1604149 | 0.77 | CCR1 (0.60) | CCR1 | |
| SCHEMBL10291848 | 0.76 | CCR1 (0.52) | CCR1ADAMTS5TACR3DPP4DPP7 | |
| SCHEMBL10297169 | 0.76 | CCR1 (0.64) | CCR1KCNH2 | |
| SCHEMBL3943177 | 0.76 | CCR1 (0.56) | CCR1KCNH2ADAMTS5 | |
| SCHEMBL10291679 | 0.76 | CCR1 (0.66) | CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | CCR1 1/4885KCNH2 3636/4885ADAMTS5 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.